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Abstract
Congenital hypogonadotropic hypogonadism (CHH) is a clinically and genetically heterogeneous congenital disease. Symp-
toms cover a wide spectrum from mild forms to complex phenotypes due to gonadotropin-releasing hormone (GnRH) 
deficiency. To date, more than 40 genes have been identified as pathogenic cause of CHH. These genes could be grouped 
into two major categories: genes controlling development and GnRH neuron migration and genes being responsible for 
neuroendocrine regulation and GnRH neuron function. High-throughput, next-generation sequencing (NGS) allows to ana-
lyze numerous gene sequences at the same time. Nowadays, whole exome or whole genome datasets could be investigated 
in clinical genetic diagnostics due to their favorable cost–benefit. The increasing genetic data generated by NGS reveal 
novel candidate genes and gene variants with unknown significance (VUSs). To provide clinically valuable genetic results, 
complex clinical and bioinformatics work are needed. The multifaceted genetics of CHH, the variable mode of inheritance, 
the incomplete penetrance, variable expressivity and oligogenic characteristics further complicate the interpretation of the 
genetic variants detected. The objective of this work, apart from reviewing the currently known genes associated with CHH, 
was to summarize the advantages and disadvantages of the NGS-based platforms and through the authors’ own practice to 
guide through the whole workflow starting from gene panel design, performance analysis and result interpretation. Based 
on our results, a genetic diagnosis was clearly identified in 21% of cases tested (8/38).
Congenital hypogonadotropic 
hypogonadism (CHH)
Congenital hypogonadotropic hypogonadism (CHH) 
as a clinically heterogeneous entity
Congenital hypogonadotropic hypogonadism (CHH) is a 
genetic condition characterized by incomplete or absent 
puberty and infertility due to central (tertiary or hypotha-
lamic) hypogonadism caused by gonadotropic hormone-
releasing hormone (GnRH) deficiency. Three clinical forms 
are distinguished by the European consensus: (1) GnRH defi-
ciency with defective sense of smell (Kallmann syndrome, 
KS), (2) isolated GnRH deficiency (normosmic CHH) and 
the third form when KS/CHH is part of a complex genetic 
syndrome (Boehm et al. 2015). CHH has an incidence of 
1:125,000 in female and 1:30,000 in males indicating the 
male predominance (Stamou and Georgopoulos 2018). CHH 
has a heterogeneous clinical appearance, and lately the con-
stitutional delay of growth and puberty (CDGP), the adult-
onset hypogonadotropic hypogonadism and the hypotha-
lamic amenorrhea are also considered as a milder end of the 
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spectrum (Stamou and Georgopoulos 2018). Most patients 
are diagnosed in adolescence due to delayed puberty. In 
male, neonate cryptorchidism and micropenis can be con-
sidered as signs of CHH, but there are no specific signs of 
CHH in female neonates (Young et al. 2019). Prepubertal 
testes and undervirilized secondary sexual features are the 
most common symptoms in males, while absence of breast 
development and primary amenorrhea occur in females as 
a consequence of CHH (Young et al. 2019). The disease 
can be diagnosed in adulthood as well by low libido, infer-
tility, bone loss and fractures when it is untreated (Young 
et al. 2019). Interestingly, in 10–20% of the cases, CHH is 
reported reversible, however, the pathophysiology behind 
this is not clearly revealed (Stamou and Georgopoulos 2018; 
Young et al. 2019). To establish the biochemical diagnosis in 
infants is challenging as GnRH neurons are active only dur-
ing mini-puberty (4–8 weeks after birth) and after that, their 
activity becomes quiescent until puberty. In adolescence, 
results of biochemical tests (basal and stimulated blood 
levels of sex hormones and gonadotropins), brain imaging 
for examination of olfactory bulbs, assessment of smell and 
evaluation of family history are parts of the routine medical 
investigations. (Naturally, additional work-ups, i.e. evalua-
tion of bones, kidneys and sexual organs, are also required 
for diagnosis and for differential diagnostic purposes (Young 
et al. 2019). Constitutional delayed of growth and puberty 
(CDGP) is defined as the lack of the start of sexual matura-
tion at an age > 2 SDs above the mean for a given population 
(Stamou and Georgopoulos 2018). There is no identifiable 
cause behind and finally puberty occurs. 50–80% of CDGP 
individuals have positive family history of the phenomenon, 
and approximately 10% of CHH patients have relatives with 
CDGP (Stamou and Georgopoulos 2018). Differentiating 
CDGP and CHH in adolescence is challenging as to date 
no gold-standard diagnostic test is known for this purpose 
(Young et al. 2019).
There are non-reproductive features as well that are 
commonly recognized in patients with CHH. Midline facial 
defects (cleft lip or palate), dental agenesis, unilateral renal 
agenesis, short metacarpals, hearing loss, synkinesia, cer-
ebellar ataxia can appear additionally to CHH (Young et al. 
2019). Furthermore, the disease can occur as part of com-
plex genetic syndromes summarized in Table 1.
Diagnostics and genetic counseling is important in CHH 
as effective therapies are available for the development of 
secondary sexual features and fertility (Maione et al. 2018; 
Young et al. 2019).
Adult onset of hypogonadotropic hypogonadism is a rare 
form of CHH. It is a non-reversible, long-lasting condition 
but the etiology and pathogenesis have to be investigated 
and demonstrated. The diagnosis can be made when all 
other acquired causes of hypogonadotropic hypogonadism 
(e.g. structural anomalies, infiltrative/inflammatory origin, 
pituitary/CNS tumors etc.) have been excluded (Stamou and 
Georgopoulos 2018).
Genetic background of CHH
CHH is heterogeneous not only clinically but also geneti-
cally. To date, more than 40 genes have been identified as 
pathogenic cause in the background of the disease (Boehm 
et al. 2015; Maione et al. 2018; Stamou and Georgopoulos 
2018). Analysis the individual CHH genes (Table 1) one 
by one exceeds the goal of our study, but these are excel-
lently reviewed in recent papers (Topaloglu and Kotan 
2016; Topaloğlu 2018; Maione et al. 2018). Genes impli-
cated in the pathogenesis of CHH are usually divided into 
two major categories (Boehm et al. 2015; Topaloğlu 2018; 
Maione et al. 2018; Stamou and Georgopoulos 2018). The 
first group consists of genes that control development and 
GnRH neuron migration. Therefore, the pathogenic variants 
of these genes are frequently associated with anosmia and 
midline developmental anomalies (Table 1). The second 
group of genes is responsible for neuroendocrine physiology 
and GnRH neuron function (either by afferent modulators 
or by regulating GnRH secretion), these can be detected in 
normosmic CHH forms. Although there are genes with mul-
tiple roles that participate in both mechanisms, their muta-
tions can be often identified in both anosmic and normosmic 
forms (Boehm et al. 2015; Maione et al. 2018; Stamou and 
Georgopoulos 2018) (Table 1).
Autosomal dominant, autosomal recessive and X-linked 
inheritance have been identified, however, with the availability 
of high-throughput next-generation sequencing at least 20% of 
CHH cases have thought to be di- or oligogenic. In these cases, 
two or more gene variants can be identified in the same patient 
(Boehm et al. 2015) (Table 1). Still, in more than half of the 
CHH cases, there is no pathogenic mutation identified. Among 
the main genetic forms of CHH, the most common autosomal 
recessively inherited types are caused by GNRHR, KISS1R 
and TACR3 variants (Maione et al. 2018). Kallmann syndrome 
caused by ANOS1 gene mutations is inherited by X-linked 
recessive trait as it is located on chromosome X. FGFR1 and 
PROK2/PROKR2 lead to autosomal dominantly inherited type 
of CHH (Boehm et al. 2015; Maione et al. 2018). Regarding 
FGFR1, nearly half, regarding PROK2/PROKR2, nearly two-
third of the cases exhibit incomplete penetrance and variable 
expressivity that complicate the determination of inheritance 
(Maione et al. 2018). Recently, a normosmic CHH patient was 
reported who inherited a pathogenic variant in GNRHR gene 
in a homozygous form due to the occurrence of uniparental 
isodisomy (Cioppi et al. 2019). (Uniparental disomy-UPD is 
a non-Mendelian inheritance pattern when an individual has 
inherited two copies of a specific chromosome (or part of it) 
from a single parent. When a chromosomal pair inherited from 
the same parent, it is called uniparental heterodisomy, when 
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two identical chromosomes are inherited it is called uniparen-
tal isodisomy (iUPD). This discovery further complicates the 
inheritance pattern of CHH and raises the possibility of the 
same phenomenon in case of other genes as well.
Individual relevance of genes in oligogenic CHH cases 
are needed to be interpreted with cautions. For instance, 
another candidate CHH gene NSMF (earlier NELF), listed in 
the expert consensus statement, has now a controversial role 
(Spilker et al. 2016). Several publications reported NSMF 
variants in CHH patients alone or in combination with a 
mutation in another gene (Miura et al. 2004; Pitteloud et al. 
2007; Xu et al. 2011) underlining again its questionable role 
(Spilker et al. 2016).
Interestingly, rare variants of TAC3, TACR3 and other 
genes are suggested to be linked with CHH reversal that 
further raises the possibility of therapy discontinuation from 
time to time to test the reversibility of CHH in these carriers 
(Gianetti et al. 2010; Boehm et al. 2015).
Variants of known CHH genes have been investigated and 
identified in CDGP and in cases with hypothalamic amenor-
rhea too. This suggests that the time of menarche and meno-
pause are genetically determined which is strongly supported 
by family histories (Stamou and Georgopoulos 2018).
In CDGP, Zhu et al. identified that variants in CHH genes 
were enriched in CDGP family members compared to unaf-
fected family members suggesting the genetic link between 
CHH and CDGP (Zhu et al. 2015). This is further supported 
by variants identified in CDGP patients in TAC3, TACR3, 
IL17RD, GNRHR, PROKR2, HS6ST1, FGFR1, FEZF1, AXL 
genes (Gianetti et al. 2012; Tusset et al. 2012; Zhu et al. 
2015; Hietamäki et al. 2017; Cassatella et al. 2018). How-
ever, results of Cassatella et al. demonstrated that CDGP 
and CHH have distinct genetic profiles that may facilitate 
the differential diagnosis in patients presenting with delayed 
puberty (Cassatella et al. 2018).
Hypothalamic amenorrhea is also a reversible dysfunc-
tional feature that can be triggered by nutritional deficit, 
extensive exercise or psychological stress. Genetic vari-
ants have been identified in FGFR1, PROKR2, GNRHR and 
ANOS1 genes suggesting that these mutations may contrib-
ute to the variable functional changes in GnRH secretion 
(Caronia et al. 2011).
CHH can be also part of complex genetic syndromes 
which are summarized by Boehm et al. and genetic back-
ground are summarized in Table 1 (Boehm et al. 2015).
Genetic testing and genetic counseling in CHH
Testing strategies
Although high-throughput screening can be recommended, 
targeted panel testing, prioritization and gene selection 
based on clinical data are also possible (Boehm et  al. Ta
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2015; Topaloğlu 2018; Stamou and Georgopoulos 2018). 
The first step is to exclude the presence of genetic syn-
dromes based on clinical findings. When a clinical geneti-
cist based on the whole clinical presentation indicates a 
specific syndrome (e.g. CHARGE sy., Bardet-Biedl sy., 
Gordon-Holmes sy., see details in Table 1) targeted gene 
testing is recommended. When complex syndromes can 
be excluded additional associated signs and symptoms 
can increase the probability of finding casual mutations 
(Boehm et al. 2015). For instance, besides anosmia/hypos-
mia, bimanual synkinesia or renal agenesis can associ-
ate with ANOS1 mutation (Fig. 1). Cleft palate/lip, dental 
agenesis and digital bone anomalies were frequently asso-
ciated with CHH caused by mutations in genes of FGF8 
signaling (FGFR1, FGF8, HS6ST1) (Costa-Barbosa et al. 
2013; Boehm et al. 2015). Hearing impairment commonly 
appeared with CHH in CHD7, SOX10 or IL17RD mutation 
carriers (Costa-Barbosa et al. 2013; Boehm et al. 2015). 
Additionally, early onset of morbid obesity with CHH 
could suggest variants in LEP, LEPR or PCSK1 genes 
(Jackson et al. 1997; Farooqi and O’Rahilly 2008). If CHH 
is associated with severe adrenal insufficiency congenital 
adrenal hypoplasia caused by NR0B1 (DAX1) is likely.
Combined pituitary hormone deficiency (CHPD) should 
also be clinically investigated/excluded as CHH and CHPD 
have overlapping genetic etiologies. If isolated CHPD is 
diagnosed, genetic testing of genes encoding the pituitary 
transcription factors (PROP1, POU1F1, LHX4, LHX3 and 
HESX1) should be recommended (Fang et al. 2016). How-
ever, lately, variants of certain CHH genes including CHD7, 
PROKR2, WDR11, FGFR1 and FGF8 have also been impli-
cated in CPHD (Raivio et al. 2012; Fang et al. 2016). Similar 
to CHH, CPHD is suggested to be a multifactorial disease 
as symptoms frequently present incomplete penetrance even 
harboring the very same mutations (Raivio et al. 2012).
Genetic testing starts with evaluation of the inherit-
ance pattern using pedigree analysis. However, Mendelian 
inheritance have been described for the majority of genes 
associated with CHH, some genes show different inherit-
ance patterns (e.g. FGFR1: AD/AR/oligogenic/de novo; 
PROK2/PROKR2: AD/AR/oligogenic), see Table 1 (Boehm 
et al. 2015; Maione et al. 2018).
Parallel with revolution of molecular genetic technolo-
gies for patients with CHH multi-gene panel testing can 
be recommended, because there is a wide overlap between 
both symptoms and genetic background (Boehm et al. 2015; 
Maione et al. 2018). Since expert consensus have been pub-
lished in 2015 (Boehm et al. 2015) several high-throughput 
multi-gene panel studies were carried out. However, there 
is no consented gene list that should be offered for patients 
providing an accurate diagnosis for the majority of cases. 
After publication of the expert consensus 7 CHH gene panel 
testing studies were reported (Table 2) (Quaynor et al. 2016; 
Aoyama et al. 2017; Wang et al. 2017; Cassatella et al. 2018; 
Zhou et al. 2018; Amato et al. 2019; Kim et al. 2019). In 
these studies, 25–261 genes were included as susceptibility 
genes of CHH. The positive detection rate varied between 
33 and 56% (Table 2). Mutations in the FGFR1 gene were 
found the most commonly (in all eight studies), ANOS1 (in 
seven studies) and CHD7, PROKR2, TACR3 and IL17RD 
variants were also frequently detected (in six studies) 
among different groups (Table 2). Analyzing the detec-
tion rate by patient number FGFR1 variants were detected 
most commonly, in an average of 11.4% of all investigated 
patients, CHD7, PROKR2 and ANOS1 in 8.4, 6.4 and 5.7% 
of patients, respectively, across all studies. All other gene 
Fig. 1  Genetic testing strategies in CHH (based on Boehm et al. 2015; Stamou and Georgopoulos 2018; Topaloğlu 2018)
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Table 2  High-throughput NGS studies investigating CHH patients
Quaynor 
et al. (2016)
Wang et al. 
(2017)
Aoyama 
et al. (2017)
Cassatella et al. (2018) Zhou et al. 
(2018)
Kim et al., 
(2019)
Amato et al. 
(2019
Current study
Nr of CHH 
patients
48 51 22 116 CHH 72 CDGP 153 28 130 38
Nr of genes 
investi-
gated
261 164 27 25 83 69 36 41
Nr of 
patients 
with 
identified 
variant
NA 26 (51%) 12 (54.5%) 59 (51%) 5 (7%) 87 (56%) 11 (39%) 43 (33%) 22 (57%)
Ratio of 
cases 
with di-/
oligogenic 
back-
ground
19% 9.8% 0% 15% 1.4% 19% not reported 6.9% 21%
Genes with 
variants 
identified 
(frequency 
of detec-
tion in the 
partciular 
cohort)
AXL (6.3%) PROKR2 
(17.6%)
CHD7 
(18.2%)
FGFR1 
(15.5%)
AXL 
(1.4%)
RELN (20.3%) FGFR1 
(14.3%)
CHD7 
(10.8%)
FGFR1 
(12.5%)
FGFR1 
(6.3%)
FGFR1 
(13.7%)
ANOS1 
(18.2%)
CHD7 
(13.8%)
FGFR1 
(1.4%)
PROKR2 
(17.6%)
CHD7 
(7.1%)
FGFR1 
(8.5%)
GLI3 (7.5%)
GLI3 
(4.2%)
CHD7 
(7.8%)
FGFR1 
(13.6%)
PROKR2 
(5.2%)
HS6ST1 
(1.4%)
CHD7 (9.8%) TACR3 
(7.1%)
IGSF10 
(5.4%)
NOTCH1 
(7.5%)
AMN1 
(2.1%)
IL17RD 
(5.9%)
TACR3 
(4.5%)
SOX10 
(4.3%)
PROKR2 
(1.4%)
ANOS1 (7.2%) PROKR2 
(3.6%)
GNRHR 
(5.4%)
MASTL 
(7.5%)
CCKBR 
(2.1%)
ANOS1 
(5.9%)
AXL 
(3.4%)
TAC3 
(1.4%)
ERBB4 (6.5%) ANOS1 
(3.6%)
WDR11 
(4.6%)
PROKR2 
(5%)
CRY1 
(2.1%)
FGF17 
(2%)
GNRHR 
(3.4%)
FEZF1 
(1.4%)
FGFR1 (6.5%) SOX3 
(3.6%)
ANOS1 
(4.6%)
AMH (5%)
CXCR4 
(2.1%)
KISS1R 
(2%)
SEMA3A 
(2.6%)
EGFR (5.9%) TACR3 
(3.8%)
JAG1 (5%)
FGF13 
(2.1%)
PROK2 
(2%)
IL17RD 
(2.6%)
LHB (5.9%) PROK2 
(3.8%)
IL17RD (5%)
GAP43 
(2.1%)
SEMA3A 
(2%)
TACR3 
(2.6%)
PLXNB1 
(0.59%)
DMXL2 
(3.1%)
PDE3A (5%)
GNRH1 
(2.1%)
SPRY4 
(2%)
ANOS1 
(1.7%)
SEMA4D 
(5.9%)
PROKR2 
(2.3%)
ANOS1 (5%)
GNRHR 
(2.1%)
FGF8 
(1.7%)
EGF (4.6%) POLR3B 
(2.3%)
GNRHR 
(5%)
IL17RD 
(2.1%)
HS6ST1 
(1.7%)
NRP2 (4.6%) IL17RD 
(2.3%)
TAC3 (2.5%)
JAG1 
(2.1%)
WDR11 
(1.7%)
B3GNT1 
(3.9%)
SPRY4 
(1.5%)
TACR3 
(2.5%)
MASTL 
(2.1%)
GNRH1 
(1.7%)
IL17RD 
(3.9%)
SOX10 
(1.5%)
AMHR2 
(2.5%)
NOS1 
(2.1%)
KISS1 
(1.7%)
NOS1 (3.9%) SEMA7A 
(1.5%)
KISS1R 
(2.5%)
NOTCH 
(2.1%)
FGF17 
(0.9%)
ROBO3 (3.9%) SEMA3A 
(1.5%)
SPRY4 
(2.5%)
NRP2 
(2.1%)
PROK2 
(0.9%)
DCC (3.3%) POLR3A 
(1.5%)
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Table 2  (continued)
Quaynor 
et al. (2016)
Wang et al. 
(2017)
Aoyama 
et al. (2017)
Cassatella et al. (2018) Zhou et al. 
(2018)
Kim et al., 
(2019)
Amato et al. 
(2019
Current study
PALM2 
(2.1%)
KISS1R 
(0.9%)
MTOR (3.3%) NSMF 
(1.5%)
PDE3A 
(2.1%)
TAC3 
(0.9%)
SEMA7A 
(3.3%)
IGFALS 
(1.5%)
PLEHKA5 
(2.1%)
DLX5 (2.6%) GNRH1 
(1.5%)
RD3 (2.1%) GNRHR 
(2.6%)
FGF8 
(1.5%)
TRAPPC9 
(2.1%)
IGF1 (2.6%) TAC3 
(0.8%)
TSPAN11 
(2.1%)
KISS1R 
(2.6%)
RNF216 
(0.8%)
PAX6 (2.6%) PNPLA6 
(0.8%)
AXL (2%) OTX2 
(0.8%)
CNTN2 (2%) IGSF1 
(0.8%)
EBF2 (2%) FLRT3 
(0.8%)
EFNA5 (2%) EBF2 
(0.8%)
MET (2%) FGF17 
(0.8%)
PLXNA1 (2%)
SEMA3A (2%)
SLIT2 (2%)
TACR3 (2%)
FEZ1 (1.3%)
CCKAR 
(1.3%)
DCAF17 
(1.3%)
EDNRB 
(1.3%)
EPHA5 (1.3%)
GHR (1.3%)
HGF (1.3%)
NRP1 (1.3%)
WDR11 
(1.3%)
CASR (0.7%)
GH1 (0.7%)
GNRH1 
(0.7%)
LEPR (0.7%)
LIF (0.7%)
NELF(NSMF) 
(0.7%)
PROK2 (0.7%)
STS (0.7%)
TLE4 (0.7%)
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variants were found less than an average of 3% in these 
patients (see details in Table 2). Di- and oligogenic cases 
occurred approximately between 10 and 20% of all cases.
Genetic counseling
Genetic screening is essential in CHH as it can be treated 
and patients could have a good reproductive prognosis upon 
treatment (see details in (Boehm et al. 2015; Maione et al. 
2018). Genetic counseling should give information on her-
itability for other family members too, and also required 
before family planning (Maione et al. 2018).
In certain cases, heritability can be determined rela-
tively easily. For instance, in case of GNRH1/GNRHR, 
TAC3/TACR3, KISS1/KISS1R, autosomal recessive inherit-
ance pattern is characteristic, while ANOS1 is inherited as 
an X-linked trait (Maione et al. 2018). However, for genes 
of which variants inherited by an autosomal dominant way, 
the penetrance and expressivity can be variable. In case of 
FGFR1 nearly half, regarding PROK2/PROKR2 nearly two-
third of the cases exhibit incomplete penetrance and variable 
expressivity complicating the determination of the inherit-
ance pattern (Maione et al. 2018). Regarding certain genes 
(e.g. FGFR1), de novo mutations are also relatively com-
mon that has to be taken into consideration when analyzing 
pedigrees.
Additionally, together with the availability of NGS, the 
main challenge is to distinguish true oligogenicity from 
rare variants which appear as incidental findings and are 
not related to the phenotype. In determination of oligogenic-
ity, genotype–phenotype co-segregation should be assessed 
by investigating both the affected and healthy family mem-
bers. In addition, in diagnosis of oligogenicity, Maione et al. 
(2018) suggested that oligogenic load has to be correlated 
with phenotype severity. There are several complicating fac-
tors (small families, not available or not compliant family 
members, incomplete penetrance and variable expressivity) 
in segregation analysis, still, it is one of the most important 
way to identify the closest evidence of pathogenicity clini-
cally besides in vitro and in vivo studies (Oliver et al. 2015; 
Maione et al. 2018). Additionally, in clinical interpretation 
of variants of unknown significance (VUSs), clinical data 
(genotype–phenotype segregation) are of utmost important.
Once heritability is assessed, risk of disease transmission 
can be discussed according to the Mendelian rules.
Prognosis has also to be discussed as approximately 20% 
of the cases appear to be spontaneously reversible. From 
genetic point of view, to date TAC3 and TACR3 loss of func-
tion variants were described to be associated with CHH 
reversal (Gianetti et al. 2010), but with the increasing data 
provided by high-throughput NGS platforms, the number of 
genes connected to this phenomenon will probably increase 
as well.
Next‑generation sequencing allows 
evaluation of sequence variants of several 
genes at the same time in a cost‑effective 
way
Formerly, genetic testing was confined to rare genetic dis-
orders due to their complexity, labour intensity and cost. 
Now, NGS-based methods are widely available allowing to 
test even hundreds of genes at the same time. Therefore, 
NGS has been rapidly integrated into laboratory diagnos-
tics workflows for identification of germline mutations in 
inherited diseases. Due to its time and cost effectiveness, it 
is especially useful in cases when several genes have been 
identified in the background of a certain genetic condition 
such as CHH.
NGS‑based platform options for clinical genetic 
diagnostics
Although the technology allows to investigate the sequence 
of the whole genome (WGS, whole genome sequencing) or 
exome (WES, whole exome sequencing) currently, the most 
prevalent applications of NGS in clinical practice are the 
evaluation of certain genes using targeted gene panels (Di 
Resta et al. 2018).
As WGS covers the whole genome (coding and noncoding 
regions) it may seem the most preferable choice in identifica-
tion of pathogenic gene mutations in inherited diseases. The 
advantage of WGS is that library preparation is straightfor-
ward as it does not require target enrichment. Additionally, 
data obtained from WGS can easily be used for detection 
of CNVs. However, among NGS approaches it gives the 
least average depth of coverage and it is still a costly tech-
nology (Di Resta et al. 2018). Also, from clinical point of 
view, the interpretation of noncoding variants and variants 
of unknown significance (VUSs) make its utility limited.
WES aims to cover all coding regions in the genome. 
Exome contains all of the protein-coding regions of genes 
and it comprises ~ 1–2% of the genome, yet contains ~ 85% 
Table 2  (continued)
Quaynor 
et al. (2016)
Wang et al. 
(2017)
Aoyama 
et al. (2017)
Cassatella et al. (2018) Zhou et al. 
(2018)
Kim et al., 
(2019)
Amato et al. 
(2019
Current study
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of known disease causing mutations. Its cost is also more 
preferable and it is a more feasible option comparing to 
WGS (Di Resta et al. 2018). Usually, the average exome 
coverage of a WES test is 90–95% due to sequence complex-
ity. WES is sometimes used by clinical laboratories by inter-
preting only genes which have been already associated with 
any disease. When mutation has not been identified data 
analysis can be extended to the remaining exome regions. 
It has been shown that WES provides diagnosis in approxi-
mately of 11–40% of cases where the clinical diagnosis were 
uncertain (Sawyer et al. 2016). Furthermore, because the 
depth of coverage for WES is not uniform the sensitivity is 
usually lower compared to those observed in case of targeted 
disease panels.
Customized targeted gene panels offer the ability to per-
form fast and low-cost screening option, therefore, currently, 
it is the most widely used NGS approach in clinical practice 
(Di Resta et al. 2018; Wang et al. 2018; Graziola et al. 2019). 
By focusing on a limited set of genes selected for certain 
clinical condition, it is able to provide high coverage that 
increases analytical sensitivity even in detection of mosai-
cism. Furthermore, because the role of genes included in 
these panels are known to be associated with the particular 
condition the detection rate (positive finding) is also higher 
compared to WES (Di Resta et al. 2018; Wang et al. 2018; 
Graziola et al. 2019). Targeted panels give the advantage 
to avoid incidental, secondary findings and to decrease the 
number of VUSs detected.
Therefore, when the genetic background is well-defined, 
targeted testing of a gene panel could offer at a relatively 
low-cost sensitive detection of genetic variants responsible 
for a disease. However, when no suspect genes stand behind 
the clinical phenotype, exome sequencing may provide a 
wider screening option, but in these cases, trio sequencing 
would allow a more comprehensive result compared to the 
“only” individual sequencing.
Workflow of an NGS‑based genetic analysis
NGS-based sequencing analysis comprises of three steps: 
(1) library preparation, (2) parallel sequencing and (3) data 
analysis and variant interpretation (Oliver et al. 2015).
Molecular genetic analysis is routinely performed using 
DNA extracted from peripheral blood or buccal mucosa. 
In our example, we used DNA samples of 38 consecutive 
patients and 2 family members with hypogonadotropic hypo-
gonadism referred to our diagnostics laboratory. Fourteen 
patients developed the disease ≤ 18 years [2 girls and 12 boys 
with an average age of 16.2 year (± 2.1 years)]. Twenty-four 
patients developed disease in adult age (3 females, 21 males 
with an average age of 31.8 years (± 12.7 years). Patient 
characteristics, clinical findings, laboratory results and 
imaging studies are included in Supplementary Table 1. Our 
study was approved by the Scientific and Research Commit-
tee of the Medical Research Council of Ministry of Health, 
Hungary (67/PI/2012). All samples were obtained after 
acquiring written informed consent from all adult patients 
and permissions were given by parents of all minors. For 
NGS-based technologies, the amount and quality of input 
DNA is an essential factor. Degradation or low concentration 
of DNA may jeopardize the analysis.
For any NGS-based strategy, library preparation is a key 
step in the laboratory workflow. The instrumentation deter-
mines the library preparations, because high-throughput 
instruments allow larger analysis. Barcodes (unique, short 
sequences) are used to label different samples enabling 
pooling patients’ samples into one reaction and decreasing 
the per-sample cost. Library preparation methods can be 
grouped into two main categories by principle used for gene 
amplifications: (1) PCR-based and (2) hybridization-based 
methods (Butz and Patócs 2019). Although processes using 
hybridization-based capture are more time consuming and 
labour intensive, those have the advantage of having greater 
tolerance against sequence variations (sequence variants and 
copy-number alteration).
The sequencing characteristics (read length, output read 
number, cost and run time) of each platform can be different 
that are needed to be taken into consideration.
For an in-house panel design (gene selection), the rec-
ommendation of the European Society of Human Genetics 
should be followed. Only genes with known relationship 
between genotype and phenotype should be included in the 
analysis for diagnostic purposes (Matthijs et al. 2016). Also, 
the guideline states that “to avoid irresponsible testing, for 
the benefit of the patients, ‘core disease gene list’ should be 
established by the clinical and laboratory experts” (Matthijs 
et al. 2016). Therefore, consensus statements and guidelines, 
OMIM (Online Mendelian Inheritance in Man) database and 
literature search should be assessed to assemble genes in a 
diagnostic panel. For CHH, there is an available European 
Consensus Statement (Boehm et al. 2015) which was used 
as a primary guide during our panel design too.
Accordingly, our panel was designed during the first half 
of 2017. Some CHH-related genes were left out, mostly 
those which have been already introduced earlier into clini-
cal practice in our laboratory (e.g. genes responsible for 
combined pituitary deficiency or adrenal diseases) (Halász 
et al. 2006; Bertalan et al. 2019) or due to the capacity of the 
applied method. Genes associated with complex syndromes 
were not present either in our selection owing to our patient 
profile. Finally, 41 genes were analyzed (see in Supplemen-
tary Table 2 and in Table 3).
We selected NimbleGene approach to create the appro-
priate hybridization capture probe set for our gene list using 
NimbleDesign Software (https ://seque ncing .roche .com/en/
produ cts-solut ions/by-categ ory/targe t-enric hment /softw are/
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nimbl e-desig n-softw are.html) targeting the region of inter-
ests (exons + /– 30 bp/exon). Capture probe synthesis was 
done by the supplier. Library was prepared following double 
capture; the library quantification was performed follow-
ing the manufacturer’s instructions (NimbleGen SeqCap EZ 
Library protocol). Sequencing runs were done on Illumina 
MiSeq instrument using MiSeq Reagent Micro Kit v2.
Sequencing data processing, performance analysis
During NGS, huge amount of data is produced which require 
special bioinformatics handling and analysis (Biesecker and 
Green 2014), therefore, appropriate hardware, software and 
expert personnel are required for data analysis (Oliver et al. 
2015). Currently, there is no gold standard, freely available 
tool or filtering settings for bioinformatics analysis related to 
clinical applications of NGS. Each laboratory has to develop 
and validate its own pipeline (Oliver et al. 2015).
First step of sequencing data analysis is base calling that 
is integrated into the instrument’s software. During the next 
step, raw sequence reads are aligned to the reference human 
genome (Sayitoğlu 2016). Quality filtering of read align-
ment defines sensitivity and specificity of the test. Using 
very strong filtering could lead to loss of variants, while 
inclusive filters can minimize false negative results but it 
will increase the burden of confirmatory analysis. Both cov-
erage depth and uniformity are important regarding detec-
tion accuracy. In germline testing, a minimum of 20 reads/
alleles are required for diagnostic purposes. On the other 
hand, as read/error ratio increases with the increase of cover-
age practically 300–500 reads/target has been suggested to 
be enough for diagnostics (Strom 2016; Deans et al. 2017; 
Butz and Patócs 2019). Even if the coverage is adequate, it 
is important to evaluate coverage uniformity in order not 
to miss certain regions falling below the detection cut-off, 
because variants not detected will not be further analyzed 
(Rizzo and Buck 2012). In certain cases, due to sequence 
complexity, 1–2% of the targeted region may not be covered 
(Rizzo and Buck 2012).
Variant calling is performed to identify alterations com-
pared to the reference sequence (Oliver et al. 2015). In this 
step, false sequence variants are omitted by investigating 
variant allele frequency (VAF) (Lee et al. 2014; Deans et al. 
2017). (VAF is the percentage of sequence reads divided 
by the overall coverage of the particular locus. In germline 
testing, VAF represents diploid zygosity (near 0 and 100% 
for homozygosity and near 50% for heterozygosity). Unfor-
tunately, results of different variant calling algorithms do 
not correlate well, therefore, to maintain technical validity, 
confirmatory tests are recommended (Trubetskoy et al. 2015; 
Matthijs et al. 2016; Muller et al. 2016). In germline NGS 
applications, Sanger sequencing is generally accepted for 
validation.
As In Vitro Diagnosis (IVD) proved NGS-based assays 
are not widely available, each laboratory has to develop 
and validate their own protocols including from sam-
ple and library preparation, bioinformatics analysis and 
quality assurance (Rehm et al. 2013). In our analysis, we 
Table 3  CHH gene list and panel performance indicated by coverage 
(mean read/base ± SD)
Gene name Ensembl gene ID Covered 
region (bp)
Avg 
coverage/
base ± SD
KISS1 ENSG00000170498 594 66 ± 14
RD3 ENSG00000198570 765 77 ± 15
CXCR4 ENSG00000121966 1128 90 ± 23
NRP2 ENSG00000118257 3813 86 ± 18
IL17RD ENSG00000144730 2997 82 ± 18
GAP43 ENSG00000172020 1062 80 ± 18
GNRHR ENSG00000109163 1164 79 ± 18
TACR3 ENSG00000169836 1695 76 ± 17
SPRY4 ENSG00000187678 1146 74 ± 12
GLI3 ENSG00000106571 5640 80 ± 15
SEMA3A ENSG00000075213 3333 64 ± 15
FGF17 ENSG00000158815 948 80 ± 15
GNRH1 ENSG00000147437 456 70 ± 17
FGFR1 ENSG00000077782 3639 83 ± 17
TRAPPC9 ENSG00000167632 5058 75 ± 17
PALM2 ENSG00000243444 1557 79 ± 17
NOTCH1 ENSG00000148400 9705 76 ± 14
NSMF ENSG00000165802 2421 72 ± 13
MASTL ENSG00000120539 3354 65 ± 15
FGF8 ENSG00000107831 1092 75 ± 13
CCKBR1 ENSG00000110148 1641 80 ± 15
FSH ENSG00000131808 567 70 ± 15
PLEKHA5 ENSG00000052126 5082 61 ± 14
PDE3A ENSG00000172572 4383 69 ± 13
TSPAN11 ENSG00000110900 1239 71 ± 12
AMN1 ENSG00000151743 1194 51 ± 13
AMHR2 ENSG00000135409 2379 83 ± 17
TAC3 ENSG00000166863 723 78 ± 15
DUSP6 ENSG00000139318 1323 74 ± 12
CRY1 ENSG00000008405 2538 64 ± 14
NOS1 ENSG00000089250 6144 87 ± 17
CDH7 ENSG00000081138 3075 72 ± 18
KISS1R ENSG00000116014 1494 49 ± 19
AMH ENSG00000104899 1980 42 ± 10
AXL ENSG00000167601 3882 85 ± 17
LHB ENSG00000104826 603 32 ± 7
PROKR2 ENSG00000101292 1332 94 ± 20
JAG1 ENSG00000101384 3834 78 ± 16
FLRT3 ENSG00000125848 2067 79 ± 20
ANOS1 ENSG00000011201 2880 41 ± 18
FGF13 ENSG00000129682 1035 39 ± 16
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followed the Genome Analysis Tool Kit (GATK) Best 
Practices guideline using the germline short variant dis-
covery (SNPs + Indels) algorithm (DePristo et al. 2011). 
A minimum coverage of 20 reads was applied as detec-
tion filter. In our gene panel, all regions were covered by 
71 ± 14 reads/base (see details regarding each gene in 
Table 3).
The accuracy depends on the depth of sequence cov-
erage therefore NGS gene panels show the highest diag-
nostic accuracy (Oliver et al. 2015). Indeed, in a recent 
study, comparing different exome sequencing platforms 
found that 93.2% of the investigated regions were cov-
ered > 10 reads (Kong et al. 2018) (of the covered regions 
the sensitivity was reported 97.5–99.99%). Comparably, in 
our panel, 97.2% of the investigated regions (86,329 bp) 
was covered > 20 read/base. Of the investigated region, 
14,532 bp was assessed by Sanger sequencing as well, 
and all detected variants were identified by both approach, 
therefore the specificity of our panel was 100%.
Variant interpretation
Variant interpretation are guided by expert recommenda-
tions for clinical diagnostics [American College of Medi-
cal Genetics and Genomics (ACMG), European Society of 
Human Genetics (ESHG)] which should be followed for all 
laboratories offering NGS-based diagnostics (Rehm et al. 
2013; Richards et al. 2015; Matthijs et al. 2016).
WGS usually identifies 3–4 million, while WES detects 
usually 15,000–20,000 variants. Therefore, variant prioriti-
zation and interpretation are needed to determine the one or 
the few pathogenic variants responsible for disease (Fig. 2). 
First step is to assess the prevalence of certain variants in 
general population-based databases to filter out frequent 
variants assuming that pathogenic variants are not common 
in the broad population. However, in oligogenic diseases, 
relatively frequent variants can have additional or genetic 
modifier effect on the phenotype (Maione et al. 2018).
Analyzing the functional consequence of a certain vari-
ant may help the interpretation. Using various algorithms 
Fig. 2  Process of molecular genetic testing by NGS from NGS data analysis to variant interpretation. See details in the text
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(Fig. 2), variants can be classified to have low, moderate or 
high impact on protein function. It has to be kept in mind 
that even synonymous variants could sometimes influence 
splicing and, therefore, amino acid composition of the 
mature protein resulting in a pathogenic variant (Gianetti 
et al. 2010; Courage et al. 2019). After classification, further 
gene, variant and disease specific databases together with 
peer-reviewed literature data (Fig. 2) can help the accurate 
interpretation (Richards et al. 2015).
To estimate the pathogenicity of variants of uncertain 
significance (VUS) is more challenging. Multiple sources 
of information (variant frequency, in silico predictions of 
variant effect on protein function and subsidiary functional 
studies) are needed to be taken into account in order to fol-
low recommendations of guidelines in categorization of a 
particular variant (Richards et al. 2015; Matthijs et al. 2016). 
In this framework, in vitro and in vivo functional assays are 
not always available. These experiments are labour inten-
sive, need longer time, and typically performed as the part 
of research.
The molecular genetic laboratory report should focus on 
containing the clinically relevant information for clinicians 
together with a brief description of all NGS quality metrics 
(technical characteristics, bioinformatics pipelines, valida-
tion), variant annotations and classification (Richards et al. 
2015; Matthijs et al. 2016). Disease-specific statements and/
or recommendation can greatly guide the interpreter in vari-
ant evaluation. The raw data and the full report should also 
be available upon request.
In our case, for variant filtering, the following param-
eters were used: minor allele frequency (MAF) cut-off 1%, 
coding properties (synonymous variants were omitted), and 
variants’ effects were evaluated by prediction softwares 
(SNPeffect—Cingolani et al. 2012 and DANN). Variant 
interpretation was done following the ACMG recommen-
dation (Richards et al. 2015). Additionally, the European 
Consensus Statement on congenital hypogonadotropic hypo-
gonadism, Human Gene Mutation Database (HGMD) and 
peer-viewed articles were searched to categorize the detected 
variants.
All identified Class V, IV and III variants (pathogenic, 
likely pathogenic and variant of unknown significance, 
VUS) were validated using conventional bidirectional 
Sanger sequencing on an Applied Biosystems 3130 Genetic 
Analyzer System. Following Sanger validation of all patho-
genic, likely pathogenic and VUS variants we found 100% 
of concordance between NGS and Sanger results.
Pathogenicity of the identified variants, genotype–
phenotype correlation
After publication of the CHH expert consensus recommen-
dation 7 NGS panel studies have been published about the 
molecular genetic analysis of CHH. Including our current 
study, a total of 588 patients with CHH and 72 patients with 
CDGP were evaluated. Using various NGS approaches 
of these patients 262 (44%) with CHH and 5 (5.5%) with 
CDGP diagnosis carried a pathogenic variant (Table 2).
Regarding phenotype–genotype correlation some authors 
reported inconclusive results and little co-segregation by 
analyzing pedigrees in their cohorts (Aoyama et al. 2017; 
Zhou et al. 2018), probably due to the complex genetic 
background of CHH. However, differences in genetic profile 
among populations are indicated in Chinese and Japanese 
cohorts (Aoyama et al. 2017; Zhou et al. 2018). Zhou et al. 
reported that in Chinese population, cryptorchidism was the 
most common accompanying feature in addition to CHH, but 
no single gene in their panel showed association with this 
abnormality (Zhou et al. 2018). Wang et al. reported that the 
frequency of PROKR2 mutations was higher in dual CHH 
patients (showing hypothalamic and/or pituitary defects 
with testicular hypoplasia) when compared to other CHH 
cases. The authors suggested that testicular development are 
affected in early life reflecting the results of animal experi-
ments where the loss of Prokr2 compromised the integrity 
of the testicular vasculature (Wang et al. 2017).
In Kallmann syndrome, anosmia/hyposmia is part of 
the clinical picture, and ANOS1, CHD7, FGFR1, PROK2, 
PROKR2, and SEMA3A variants were reported to be 
involved in isolated congenital anosmia (Alkelai et al. 2017). 
The genetic background of CHH reversal is still unclear, 
however, the recently identified IGSF10 and GNRHR vari-
ants in addition to previously reported TAC3 and TACR3 
variants need further studies for clarification of their patho-
genic role (Amato et al. 2019).
The genetic background of CDGP and CHH share 
common aspects, they also have distinct profiles. In CHH 
patients, both mutations and oligogenicity of CHH genes 
have been more commonly identified compared to CDGP 
(Cassatella et al. 2018). In turn, the genetic profile of CDGP 
resembled more closely to those founded in control cohort. 
No pathogenic alterations, but frequent (MAF 1.0–2.5%) 
genetic variants have been more commonly detected in 
CDGP compared to controls suggesting their genetic modi-
fier’s role (Cassatella et al. 2018).
In CHH, oligogenicity was reported between 0 and 19% 
(Table 2). Interestingly, in Japanese populations Aoyama 
et al. did not find any patients with CHH caused by di-/
oligogenic mutations (Aoyama et al. 2017) while Quaynor 
et al. described that the majority of the suggested di- and oli-
gogenic background could be supported by pedigree analysis 
(9/11 pedigrees) in their cohort (Quaynor et al. 2016). Nev-
ertheless, others suggested that with the increase of the num-
bers of genes investigated the detection rate of oligogenicity 
will increase (Amato et al. 2019) making difficult to prove 
the true role of di/oligogenic findings (Maione et al. 2018).
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Our panel identified a total of 31 variants in 22 probands 
(1)13 patients with only 1 variant per individual; (2) 1 
patient with compound heterozygous variants in the GNRHR 
gene; (3) 8 patients with 2 heterozygous variants in two dif-
ferent genes (digenic case). The digenic rate was 21% (8/38). 
The eight pathogenic/likely pathogenic variants, detected in 
eight patients, hence the genetic cause was clearly identified 
in 21% of cases tested. (8/38 = 21%). In three patients the 
pathogenic mutations were detected together with variants 
of unknown significance (VUSs) (Patient IDs: 10, 29 and 
31). In addition, in 14 patients, only VUSs were identified 
(in 6 patients, 2 and in 8 patients, 1 VUS) which need further 
studies (Table 4). Grouping our patients into adult and pedi-
atric groups, our data show that clearly pathogenic variants 
in adult patients were identified in 7 (29%; 7/24), while in 1 
pediatric cases (7%; 1/14).
In pediatric cases where healthy parents were available 
for genetic test, we performed family screening. Healthy par-
ents of patients with IDs “26”, “33” and “37” were available 
for assessment of variant pathogenicity. By sequencing the 
particular variants in unaffected parents, we concluded that 
combination of SPRY4 p.Cys209Tyr and AMH p.Arg254Pro 
variants were probably not disease causing as the healthy 
father also carried the same genotype. Our family screen-
ing suggests that the originally predicted as likely patho-
genic variant (AMHR2 p.Arg495Gln) is benign for CHH and 
might be VUS for delayed puberty because the unaffected 
father carried the same variant in heterozygous form. The 
co-existence of TAC3 p.His83Pro with MASTL p.His707Leu 
(Patient “26”) could be potentially pathogenic as they were 
inherited from different parents. Naturally, in CDGP cases, 
follow-up time (onset of puberty could spontaneously occur) 
and further studies will possibly clarify the pathogenicity of 
these variants.
During the family screening of our case, Patient ID “9” 
the same pathogenic mutation was identified in his clinically 
affected brother (Patient ID “10”). There are phenotypes are 
similar, however, in Patient ID “10” anosmia was present.
It is noteworthy that some alterations (such as repetitive 
sequences, copy-number variations, long insertion–dele-
tions, structural variants, aneuploidy or epigenetic altera-
tions) are not well detectable by NGS methods Therefore, 
when these types of alterations are expected the appropri-
ate method (such as multiplex ligation probe amplification 
(MLPA) or microarray-based comparative genomic hybridi-
zation (aCGH)) should be used.
Summary and conclusion
Congenital hypogonadotropic hypogonadism has a het-
erogeneous clinical phenotype and genetic background. 
Especially in pediatric cases, even clinical diagnosis can be 
challenging (ie. pubertal delay vs. hypogonadism). Genet-
ics data regarding hypogonadotropic hypogonadism with 
the wider availability of next-generation sequencing are 
increasing but appropriate tool and expertise are needed for 
correct interpretation of these results in clinical practice. 
Based on recent data, in more 50% of cases, the disease 
causing genetic alterations could be found. In house devel-
oped gene panels together with appropriate validation steps 
have at least the same diagnostic accuracy as the WES. The 
main challenge in NGS-based methods is the interpretation 
of variants with unknown significance. For clinical point of 
view, a great majority of data generated by exome and panel 
sequencing have still been waiting for clinical validation. 
The potentially new candidate genes and variants have to be 
further analyzed functionally (in vitro and in vivo animal 
experiments) together with thorough clinical genotype–phe-
notype investigations to prove their disease causing effects. 
The latter is especially challenging in CHH as the clinical 
phenotype cover a broad spectrum even in cases harboring 
the same mutation. In CHH, another great challenge is to 
distinguish true oligogenic inheritance from incidental, rare 
findings that are not in relation with CHH. The difficulty 
in determining inheritance due to non-complete penetrance 
and variable expressivity together with oligogenicity could 
mean a difficult situation for genetic counselors. However, 
over time with the increasing genetic data linked to clinical 
information will reveal the complex genetic landscape of 
CHH and eventually it will help variant interpretation.
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